CRON Quote, Financials, Valuation and Earnings

Edesa Biotech, Inc. has a net margin of 77.94% compared to Cronos Group, Inc.'s net margin of --. Cronos Group, Inc.'s return on equity of 3.69% beat Edesa Biotech, Inc.'s return on equity of -77.48%.

Cronos Group, Inc. has a consensus price target of $2.10, signalling downside risk potential of -23.17%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 746.15%. Given that Edesa Biotech, Inc. has higher upside potential than Cronos Group, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Cronos Group, Inc..

Cronos Group, Inc. has a beta of 0.657, which suggesting that the stock is 34.292% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

Cronos Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Cronos Group, Inc. quarterly revenues are $36.3M, which are larger than Edesa Biotech, Inc. quarterly revenues of --. Cronos Group, Inc.'s net income of $28.3M is higher than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Cronos Group, Inc.'s price-to-earnings ratio is 29.34x while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group, Inc. is 7.97x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience Corp. has a net margin of 77.94% compared to Cronos Group, Inc.'s net margin of -2178.51%. Cronos Group, Inc.'s return on equity of 3.69% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.

Cronos Group, Inc. has a consensus price target of $2.10, signalling downside risk potential of -23.17%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $5.33 which suggests that it could grow by 852.38%. Given that Lexaria Bioscience Corp. has higher upside potential than Cronos Group, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Cronos Group, Inc..

Cronos Group, Inc. has a beta of 0.657, which suggesting that the stock is 34.292% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.

Cronos Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

Cronos Group, Inc. quarterly revenues are $36.3M, which are larger than Lexaria Bioscience Corp. quarterly revenues of $174K. Cronos Group, Inc.'s net income of $28.3M is higher than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Cronos Group, Inc.'s price-to-earnings ratio is 29.34x while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group, Inc. is 7.97x versus 14.29x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of 77.94% compared to Cronos Group, Inc.'s net margin of --. Cronos Group, Inc.'s return on equity of 3.69% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Cronos Group, Inc. has a consensus price target of $2.10, signalling downside risk potential of -23.17%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 472.27%. Given that Oncolytics Biotech, Inc. has higher upside potential than Cronos Group, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Cronos Group, Inc..

Cronos Group, Inc. has a beta of 0.657, which suggesting that the stock is 34.292% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Cronos Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Cronos Group, Inc. quarterly revenues are $36.3M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Cronos Group, Inc.'s net income of $28.3M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Cronos Group, Inc.'s price-to-earnings ratio is 29.34x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group, Inc. is 7.97x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tilray Brands, Inc. has a net margin of 77.94% compared to Cronos Group, Inc.'s net margin of 0.72%. Cronos Group, Inc.'s return on equity of 3.69% beat Tilray Brands, Inc.'s return on equity of -84.8%.

Cronos Group, Inc. has a consensus price target of $2.10, signalling downside risk potential of -23.17%. On the other hand Tilray Brands, Inc. has an analysts' consensus of $16.17 which suggests that it could grow by 59.28%. Given that Tilray Brands, Inc. has higher upside potential than Cronos Group, Inc., analysts believe Tilray Brands, Inc. is more attractive than Cronos Group, Inc..

Cronos Group, Inc. has a beta of 0.657, which suggesting that the stock is 34.292% less volatile than S&P 500. In comparison Tilray Brands, Inc. has a beta of 1.758, suggesting its more volatile than the S&P 500 by 75.794%.

Cronos Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group, Inc. pays -- of its earnings as a dividend. Tilray Brands, Inc. pays out -- of its earnings as a dividend.

Cronos Group, Inc. quarterly revenues are $36.3M, which are smaller than Tilray Brands, Inc. quarterly revenues of $209.5M. Cronos Group, Inc.'s net income of $28.3M is higher than Tilray Brands, Inc.'s net income of $1.5M. Notably, Cronos Group, Inc.'s price-to-earnings ratio is 29.34x while Tilray Brands, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group, Inc. is 7.97x versus 3.54x for Tilray Brands, Inc.. Usually stocks with elevated PS ratios are considered overvalued.